Welcome to our dedicated page for Revelation Biosciences SEC filings (Ticker: REVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revelation Biosciences, Inc. (REVB) SEC filings page on Stock Titan provides organized access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated summaries to help interpret complex documents. Revelation Biosciences is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based TLR4 agonist targeting inflammation-driven conditions such as acute kidney injury, chronic kidney disease, post-surgical infection, and severe burn-related hyperinflammation.
Through this page, readers can review current and historical filings drawn from the SEC’s EDGAR system, including Form 8-K reports on material events and financing transactions, and definitive proxy statements on Schedule 14A for special meetings of stockholders. For example, recent 8-K filings describe warrant exercise inducement agreements, gross proceeds from warrant exercises, and the use of those proceeds for clinical development and corporate purposes. DEF 14A proxy statements outline proposals to authorize the issuance of common stock underlying new classes of warrants, explain Nasdaq share issuance limits, and provide details on virtual special meetings.
AI-powered tools on Stock Titan summarize lengthy filings, highlight key sections, and surface items such as capital raises, warrant terms, and changes affecting stockholder rights. Users can quickly identify disclosures related to warrant structures (including REVBW redeemable warrants), share authorization proposals, and other governance matters without reading every page manually.
In addition to event-driven reports, investors can use this filings hub to track how Revelation Biosciences describes its business focus on Gemini and inflammation modulation over time. As new quarterly, annual, and current reports are filed, they are added with real-time updates and concise AI explanations, helping users understand the regulatory context behind REVB’s clinical, financial, and capital markets activities.
Revelation Biosciences (REVB) reported an insider equity award. Director Jess Roper acquired 15,625 shares of Common Stock on 10/29/2025 at $1.28 per share, coded as an acquisition. Following the transaction, the director beneficially owned 15,686 shares, held directly.
The shares were a Restricted Stock Grant under the 2021 Equity Incentive Plan and vest 100% on January 28, 2026.
Revelation Biosciences (REVB) canceled its adjourned Special Meeting of Stockholders scheduled for October 29, 2025 due to a technical difficulty that prevented some stockholders from voting all of their shares.
The company set a new record date of October 29, 2025 for a new Special Meeting to be held on December 3, 2025. The disclosure is furnished under Item 7.01 (Regulation FD), and a related press release is included as Exhibit 99.1.
Revelation Biosciences (REVB) announced that its Special Meeting of Stockholders held on October 15, 2025 was adjourned to October 29, 2025 because a quorum was not present. The company disclosed this under Regulation FD, noting the information is being furnished, not filed.
The update was provided via an 8-K with an accompanying press release as Exhibit 99.1. The adjournment allows additional time to achieve the required shareholder participation to conduct the meeting’s business.
Revelation Biosciences, Inc. filed an amended shelf registration (Form S-3/A) to register shares of common stock issuable upon exercise of Class I Common Stock Warrants issued under an inducement letter dated September 10, 2025. The warrants become exercisable after stockholder approval and remain exercisable for five years at an exercise price of $2.20 per share. The company is not selling shares under this prospectus and will not receive proceeds from any secondary sales, but may receive up to approximately $28,743,000 if all registered warrants are exercised for cash.
The prospectus discloses beneficial ownership and address details for three selling stockholders holding roughly 4.52 million, 4.025 million, and 4.52 million Class I warrants, respectively, and notes 4.99% and 9.99% beneficial ownership exercise limitations. The company will pay registration fees and expenses and incorporates its recent SEC filings by reference, including annual and quarterly reports and multiple current reports filed through September 15, 2025.
Revelation Biosciences, Inc. is soliciting shareholder votes at a Special Meeting to approve a proposal limiting conversions under certain warrants issued September 11, 2025, which could trigger Nasdaq’s 20% share issuance cap. The proposal would constrain issuances under those warrants to avoid exceeding the Exchange Cap. On the record date there were 2,339,306 shares outstanding, with each share entitled to one vote. The warrant holders—Sabby Volatility Warrant Master Fund, Ltd., Armistice Capital Master Fund Ltd. and Hudson Bay Master Fund Ltd.—are interested parties but have agreed to vote their shares in the same proportion as non-interested stockholders. The board recommends voting FOR both Proposal 1 (the conversion limitation) and Proposal 2 (adjournment if insufficient proxies). Shareholders may vote by returning the proxy card or attend and vote telephonically; beneficial owners must obtain a broker or nominee proxy to vote.
Revelation Biosciences, Inc. filed a shelf registration to register shares issuable upon exercise of Class I Common Stock Warrants issued under an inducement letter dated September 10, 2025. The Class I Common Stock Warrants are exercisable for five years after stockholder approval at an exercise price of $2.20 per share. The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling stockholders, but it may receive up to approximately $28,743,000 if all warrants are exercised for cash. The company will pay the fees and expenses of registration. The warrants held by three selling stockholders are reported as 4,519,998, 4,025,001, and 4,520,001 warrants respectively and are subject to 4.99% and 9.99% beneficial ownership limits that can prevent exercise if ownership would exceed those thresholds. The prospectus incorporates prior SEC filings listed in the text.
Revelation Biosciences, Inc. entered into warrant exercise inducement agreements with certain holders of 13,065,000 existing Class H Common Stock Warrants, leading to the cash exercise of warrants for approximately $9.6 million in aggregate gross proceeds at an exercise price of $2.20 per share. In return, the company agreed to issue 13,065,000 new Class I Common Stock Warrants, also with a $2.20 exercise price, which will become exercisable only after stockholder approval and then remain exercisable for five years from that approval date.
The company plans to use the net proceeds to fund clinical development, working capital, and general corporate purposes. The existing warrant share issuance is covered by an effective Form S-1 registration statement, while the new Class I Warrants were issued in a private placement exemption and their underlying shares are expected to be registered for resale on a future Form S-3. Revelation agreed to pay Roth Capital Partners, LLC a cash fee equal to 8% of the aggregate gross proceeds plus expense reimbursement for advisory services related to this transaction.